Clinical Trial: Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase 1 Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine

Brief Summary: The purpose of this phase 1 study is to evaluate the safety and immunogenicity of rPA102 vaccine, using anthrax vaccine adsorbed (AVA) as a comparator.

Detailed Summary:
Sponsor: VaxGen

Current Primary Outcome: Safety and immunogenicity of 3 doses over 4 different dose ranges.

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: VaxGen

Dates:
Date Received: February 8, 2005
Date Started: June 2003
Date Completion:
Last Updated: June 23, 2005
Last Verified: February 2005